MA38085A1 - Nouveau procédé pour la production de composés à utiliser dans le traitement du cancer - Google Patents

Nouveau procédé pour la production de composés à utiliser dans le traitement du cancer

Info

Publication number
MA38085A1
MA38085A1 MA38085A MA38085A MA38085A1 MA 38085 A1 MA38085 A1 MA 38085A1 MA 38085 A MA38085 A MA 38085A MA 38085 A MA38085 A MA 38085A MA 38085 A1 MA38085 A1 MA 38085A1
Authority
MA
Morocco
Prior art keywords
production
cancer
compounds
treatment
new process
Prior art date
Application number
MA38085A
Other languages
English (en)
Other versions
MA38085B1 (fr
Inventor
C Gregory Sowell
Sriram Naganathan
Nathan Guz
Matthew Pfeiffer
Tracy Bostick
Jason Yang
Amit Srivastava
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MA38085A1 publication Critical patent/MA38085A1/fr
Publication of MA38085B1 publication Critical patent/MA38085B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

L'invention concerne un procédé pour la production d'un composé de formule i. Ledit composé de formule i est un inhibiteur de mek et peut ainsi être utilisé pour traiter le cancer.
MA38085A 2012-10-12 2013-10-14 Nouveau procédé pour la production de composés à utiliser dans le traitement du cancer MA38085B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261713104P 2012-10-12 2012-10-12
PCT/US2013/064866 WO2014059422A1 (fr) 2012-10-12 2013-10-14 Nouveau procédé pour la production de composés à utiliser dans le traitement du cancer

Publications (2)

Publication Number Publication Date
MA38085A1 true MA38085A1 (fr) 2018-08-31
MA38085B1 MA38085B1 (fr) 2018-11-30

Family

ID=49474740

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38085A MA38085B1 (fr) 2012-10-12 2013-10-14 Nouveau procédé pour la production de composés à utiliser dans le traitement du cancer

Country Status (31)

Country Link
US (4) US9771347B2 (fr)
EP (1) EP2909188B1 (fr)
JP (2) JP6300042B2 (fr)
KR (1) KR102204520B1 (fr)
CN (2) CN108948043B (fr)
AU (1) AU2013328929B2 (fr)
BR (1) BR112015008113B1 (fr)
CA (1) CA2889466C (fr)
CL (1) CL2015000926A1 (fr)
CR (2) CR20200237A (fr)
EA (1) EA030613B1 (fr)
ES (1) ES2671502T3 (fr)
GE (1) GEP201706690B (fr)
HK (2) HK1213567A1 (fr)
HR (1) HRP20180670T1 (fr)
IL (1) IL238116B (fr)
IN (1) IN2015DN03928A (fr)
MA (1) MA38085B1 (fr)
MX (2) MX2015004660A (fr)
MY (1) MY186549A (fr)
NZ (1) NZ706723A (fr)
PE (3) PE20151494A1 (fr)
PH (1) PH12015500785A1 (fr)
PL (1) PL2909188T3 (fr)
SA (1) SA515360271B1 (fr)
SG (1) SG11201502795VA (fr)
SI (1) SI2909188T1 (fr)
TR (1) TR201807861T4 (fr)
UA (1) UA115455C2 (fr)
WO (1) WO2014059422A1 (fr)
ZA (1) ZA201502349B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY186549A (en) 2012-10-12 2021-07-26 Exelixis Inc Novel process for making compounds for use in the treatment of cancer
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
SI3881833T1 (sl) 2015-06-30 2024-03-29 Genentech, Inc., Tablete s takojšnjim sproščanjem, ki vsebujejo zdravilo in postopek za oblikovanje tablet
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
CN105330643B (zh) * 2015-12-09 2017-12-05 苏州明锐医药科技有限公司 卡比替尼的制备方法
CN106045969B (zh) * 2016-05-27 2019-04-12 湖南欧亚药业有限公司 一种卡比替尼的合成方法
MX2019001635A (es) 2016-08-12 2019-06-10 Genentech Inc Terapia de combinacion con un inhibidor de mek, un inhibidor del eje de pd-1, y un inhibidor de vegf.
BR112019005815A2 (pt) 2016-09-29 2019-06-25 Genentech Inc métodos de tratamento de um indivíduo com câncer de mama, kit para o tratamento de câncer de mama e combinação de fármacos para terapia de câncer de mama
WO2020187674A1 (fr) 2019-03-15 2020-09-24 Sandoz Ag Hémisuccinate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl) azétidin-1-yl]méthanone cristallin
KR20230156731A (ko) 2021-03-09 2023-11-14 제넨테크, 인크. 뇌암 치료에 이용하기 위한 벨바라페닙
JP2024514112A (ja) 2021-04-06 2024-03-28 ジェネンテック， インコーポレイテッド ベルバラフェニブおよびコビメチニブを用いた併用療法、またはベルバラフェニブ、コビメチニブおよびアテゾリズマブを用いた併用療法

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1563587A (en) * 1924-09-20 1925-12-01 Raney Murray Method of preparing catalytic material
US1628190A (en) * 1926-05-14 1927-05-10 Raney Murray Method of producing finely-divided nickel
US1915473A (en) * 1930-12-31 1933-06-27 Raney Murray Method of preparing catalytic material
US4510139A (en) 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
US5155110A (en) 1987-10-27 1992-10-13 Warner-Lambert Company Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
AU685933B2 (en) 1994-04-01 1998-01-29 Shionogi & Co., Ltd. Oxime derivative and bactericide containing the same as active ingredient
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
WO1998037881A1 (fr) 1997-02-28 1998-09-03 Warner Lambert Company Methode de traitement ou de prevention du choc septique par administration d'un inhibiteur mek
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
EP0993439B1 (fr) 1997-07-01 2004-09-29 Warner-Lambert Company LLC Derives d'acide benzhydroxamique phenylamino 4-bromo ou 4-iodo et utilisation de ces derniers en tant qu'inhibiteurs de mek
WO1999001421A1 (fr) 1997-07-01 1999-01-14 Warner-Lambert Company Derives d'acide benzoique 2-(4-bromo ou 4-iodo phenylamino) et utilisation de ces derniers en tant qu'inhibiteurs de mek
US6974878B2 (en) 2001-03-21 2005-12-13 Symyx Technologies, Inc. Catalyst ligands, catalytic metal complexes and processes using same
CA2346684A1 (fr) 1998-12-15 2000-06-22 Warner-Lambert Company Technique de prevention du rejet de greffe par utilisation d'un inhibiteur du mek
CA2346448A1 (fr) 1998-12-16 2000-06-22 Warner-Lambert Company Traitement de l'arthrite a l'aide d'inhibiteurs de la mek
EE200100339A (et) 1998-12-22 2002-10-15 Warner-Lambert Company Kombineeritud kemoteraapia
KR20000047461A (ko) 1998-12-29 2000-07-25 성재갑 트롬빈 억제제
EP1140067A1 (fr) 1999-01-07 2001-10-10 Warner-Lambert Company Methode antivirale utilisant des inhibiteurs de mek
WO2000040235A2 (fr) 1999-01-07 2000-07-13 Warner-Lambert Company Traitement de l'asthme a l'aide d'inhibiteurs de mek
CA2355470C (fr) 1999-01-13 2008-09-30 Warner-Lambert Company Les benzoheterocycles et leur utilisation comme inhibiteurs de mek
NZ513432A (en) 1999-01-13 2004-02-27 Warner Lambert Co 1-heterocycle substituted diarylamines
ATE309205T1 (de) 1999-01-13 2005-11-15 Warner Lambert Co Benzenesulfonamid-derivative und ihre verwendung als mek-inhibitoren
WO2000041505A2 (fr) 1999-01-13 2000-07-20 Warner-Lambert Company 4'heteroaryle diarylamines
CA2348236A1 (fr) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, et 4-arylthio diarylamines et leurs derives comme inhibiteurs selectifs de mek
JP2003504400A (ja) 1999-07-16 2003-02-04 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤を用いた慢性痛の治療方法
PL352705A1 (en) 1999-07-16 2003-09-08 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
HUP0202319A3 (en) 1999-07-16 2004-12-28 Warner Lambert Co Use of mek inhibitors for the preparation of pharmaceutical compositions treating chronic pain
DK1202724T3 (da) 1999-07-16 2004-01-26 Warner Lambert Co Fremgangsmåde til behandling af kronisk smerte under anvendelse af mek-inhibitorer
MX226123B (es) 1999-09-17 2005-02-07 Millennium Pharm Inc Benzamidas e inhibidores del factor xa relacionadas.
JP2003527379A (ja) 2000-03-15 2003-09-16 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Ｍｅｘ阻害物質としての５−アミド置換ジアリールアミン類
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
DZ3401A1 (fr) 2000-07-19 2002-01-24 Warner Lambert Co Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
EA200300187A1 (ru) * 2000-08-25 2003-08-28 УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл Эл Си Способ получения n-арилантраниловых кислот и их производных
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
US20040039208A1 (en) * 2001-07-20 2004-02-26 Chen Michael Huai Gu Process for making n-aryl-anthranilic acids and their derivatives
DE10141266A1 (de) 2001-08-21 2003-03-06 Syntec Ges Fuer Chemie Und Tec Elektrolumineszierende Derivate der 2,5-Diamino-terephthalsäure und deren Verwendung in organischen Leuchtdioden
US7085492B2 (en) 2001-08-27 2006-08-01 Ibsen Photonics A/S Wavelength division multiplexed device
IL160967A0 (en) 2001-10-31 2004-08-31 Pfizer Prod Inc Nicotinic acetylcholine receptor agonists in the treatment of restless legs syndrome
DOP2003000556A (es) 2002-01-23 2003-10-31 Warner Lambert Co Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
JP2005515253A (ja) 2002-01-23 2005-05-26 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Ｎ−（４−置換フェニル）−アントラニル酸ヒドロキサメートエステル
KR20040098013A (ko) 2002-03-13 2004-11-18 어레이 바이오파마 인크. Ｍｅｋ 억제제로서의 ｎ3 알킬화된 벤즈이미다졸 유도체
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
SI1482932T1 (sl) 2002-03-13 2010-02-26 Array Biopharma Inc N3-alkilirani derivati benzimidazola kot inhibitorji mek
AU2003238915B2 (en) 2002-06-11 2008-02-21 Merck & Co., Inc. (halo-benzo carbonyl)heterobicyclic p38 kinase inhibiting agents
GB0214268D0 (en) 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
AU2003248813A1 (en) 2002-07-05 2004-01-23 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
WO2004078116A2 (fr) 2003-03-03 2004-09-16 Array Biopharma, Inc. Inhibiteurs de la p 38 et leurs procedes d'utilisation
TW200505834A (en) 2003-03-18 2005-02-16 Sankyo Co Sulfamide derivative and the pharmaceutical composition thereof
JP2005162727A (ja) 2003-03-18 2005-06-23 Sankyo Co Ltd スルファミド誘導体及びその医薬組成物
GB0308185D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
BRPI0410653A (pt) 2003-06-20 2006-07-04 Celltech R&D Ltd composto, composição farmacêutica, e, uso de um composto ou um sal, solvato, hidrato ou n-óxido farmaceuticamente aceitável do mesmo
WO2005000818A1 (fr) 2003-06-27 2005-01-06 Warner-Lambert Company Llc Derives de 4-[phenylamino (substitue)]-2-pyridone a substitution en 5 en tant qu'inhibiteurs de la mek
US20050049276A1 (en) 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
ES2331246T3 (es) 2003-07-24 2009-12-28 Warner-Lambert Company Llc Derivados de benzamidazol como inhibidores del mek.
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
WO2005028426A1 (fr) 2003-09-19 2005-03-31 Chugai Seiyaku Kabushiki Kaisha Nouveau derive de 4-phenylamino-benzaldoxime et son utilisation en tant qu'inhibiteur de mek
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
AU2004293436B2 (en) 2003-11-19 2010-12-09 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
EP1694673B1 (fr) 2003-12-08 2008-01-16 F.Hoffmann-La Roche Ag Derives de thiazole
TWI361066B (en) 2004-07-26 2012-04-01 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
EA013212B1 (ru) * 2004-10-20 2010-04-30 Лаборатуар Сероно Са 3-ариламинопиридиновые производные
WO2006061712A2 (fr) 2004-12-10 2006-06-15 Pfizer Inc. Utilisation d'inhibiteurs de mek dans le traitement d'une croissance cellulaire anormale
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
CA3052368A1 (fr) 2005-10-07 2007-04-19 Exelixis, Inc. Azetidines comme inhibiteurs de mek
ATE539752T1 (de) 2006-08-16 2012-01-15 Exelixis Inc Verwendung von pi3k- und mek-modulatoren bei der krebsbehandlung
CN105106199A (zh) 2006-12-14 2015-12-02 埃克塞利希斯股份有限公司 使用mek抑制剂的方法
MY186549A (en) 2012-10-12 2021-07-26 Exelixis Inc Novel process for making compounds for use in the treatment of cancer
EP3103789B1 (fr) 2014-02-07 2018-10-31 Sumitomo Chemical Company Limited Procédé de production de (r)-1,1,3-triméthyl-4-aminoindane
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona

Also Published As

Publication number Publication date
PH12015500785B1 (en) 2015-06-15
US11414396B2 (en) 2022-08-16
CL2015000926A1 (es) 2015-08-28
ZA201502349B (en) 2019-12-18
EA030613B1 (ru) 2018-08-31
EP2909188B1 (fr) 2018-03-07
JP6300042B2 (ja) 2018-03-28
CN108948043B (zh) 2021-05-04
IL238116B (en) 2018-06-28
GEP201706690B (en) 2017-06-26
HK1213567A1 (zh) 2016-07-08
CA2889466C (fr) 2021-09-14
US20170349569A1 (en) 2017-12-07
MX2020005533A (es) 2020-10-12
PE20151494A1 (es) 2015-11-06
MX2015004660A (es) 2015-08-07
US10239858B2 (en) 2019-03-26
PE20191818A1 (es) 2019-12-27
HRP20180670T1 (hr) 2018-07-13
MY186549A (en) 2021-07-26
PL2909188T3 (pl) 2018-08-31
BR112015008113B1 (pt) 2022-05-24
SG11201502795VA (en) 2015-05-28
CN104837826A (zh) 2015-08-12
JP2018052973A (ja) 2018-04-05
PE20200387A1 (es) 2020-02-24
KR20150067339A (ko) 2015-06-17
UA115455C2 (uk) 2017-11-10
EA201590700A1 (ru) 2015-09-30
CR20200237A (es) 2020-07-26
CR20150245A (es) 2015-11-19
EP2909188A1 (fr) 2015-08-26
AU2013328929B2 (en) 2018-01-04
CA2889466A1 (fr) 2014-04-17
US20200392104A1 (en) 2020-12-17
ES2671502T3 (es) 2018-06-06
US9771347B2 (en) 2017-09-26
PH12015500785A1 (en) 2015-06-15
WO2014059422A1 (fr) 2014-04-17
BR112015008113A2 (pt) 2017-07-04
US20150210668A1 (en) 2015-07-30
KR102204520B1 (ko) 2021-01-20
SI2909188T1 (en) 2018-07-31
JP2015533175A (ja) 2015-11-19
AU2013328929A1 (en) 2015-04-30
NZ706723A (en) 2018-07-27
CN108948043A (zh) 2018-12-07
TR201807861T4 (tr) 2018-06-21
CN104837826B (zh) 2018-07-27
MA38085B1 (fr) 2018-11-30
US20190185447A1 (en) 2019-06-20
SA515360271B1 (ar) 2016-05-19
HK1213878A1 (zh) 2016-07-15
US10793541B2 (en) 2020-10-06
IN2015DN03928A (fr) 2015-10-02

Similar Documents

Publication Publication Date Title
MA38085B1 (fr) Nouveau procédé pour la production de composés à utiliser dans le traitement du cancer
CY1122272T1 (el) ΕΝΩΣΕΙΣ 3-ΚΥΚΛΟΕΞΕΝΥΛ ΚΑΙ ΚΥΚΛΟΕΞΥΛ ΥΠΟΚΑΤΕΣΤΗΜΕΝΟΥ ΙΝΔΟΛΙΟΥ ΚΑΙ ΙΝΔΑΖΟΛΙΟΥ ΩΣ RORgammaT ΑΝΑΣΤΟΛΕΙΣ ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
TN2017000204A1 (en) Triazolopyrimidine compounds and uses thereof
EA201891553A1 (ru) Ингибиторы syk
MA44820A1 (fr) Amides hétérocycliques a utiliser en tant qu'inhibiteurs de kinase
PH12017501419B1 (en) Therapeutically active compounds and their methods of use
EA201690094A1 (ru) Ингибиторы syk
MA40076A (fr) Inhibiteurs de syk
MA38239A1 (fr) Nouveaux dérivés de pyridine
UA110338C2 (en) Chemical compounds
MX350432B (es) Compuestos terapeuticamente activos y sus metodos de empleo.
UA107652C2 (en) Carbazole compounds and therapeutic uses of the compounds
AR088983A1 (es) Procedimiento para la preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas
MX2016002125A (es) Compuesto novedoso sustituido con quinolina.
EA201391591A1 (ru) Лечение множественной миеломы
NZ719444A (en) Novel dgat2 inhibitors
MA38410A1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
MA37676B1 (fr) Nouveau promédicament de rebamipide, son procédé de fabrication et son utilisation
MA39110B1 (fr) Nouveau composé pour le traitement de l'hypoglycémie grave
MA39109A1 (fr) Nouveau composé pour le traitement de l'hypoglycémie grave
MA35534B1 (fr) Composé pour le traitement et la prophylaxie de la maladie du virus respiratoire syncytial
MA37685A1 (fr) Composés acide diméthyl-benzoïque inhibiteurs selectifs de l'ep4 pour utilisation dans le traitement d'etats pathologiques inflammatoires tels que l'arthrite
PL418655A1 (pl) Kwas 3,7,11,15-tetrametylo-3-winyloheksadekanowy oraz sposób otrzymywania kwasu 3,7,11,15-tetrametylo-3-winyloheksadekanowego
MA39062B1 (fr) Nouveau procede de synthese du 7-methoxy-naphtalene-1-carbaldehyde et application a la synthese de l'agomelatine
MA35887B1 (fr) Nouveaux dérivés morpholynyle utiles comme inhibiteurs de mogat-2